Parag Goyal1, Jerard Kneifati-Hayek2, Alexi Archambault3, Krisha Mehta4, Emily B Levitan5, Ligong Chen5, Ivan Diaz6, James Hollenberg3, Joseph T Hanlon7, Mark S Lachs8, Mathew S Maurer9, Monika M Safford3. 1. Division of Cardiology, Weill Cornell Medicine, New York, New York; Division of General Internal Medicine, Weill Cornell Medicine, New York, New York. Electronic address: pag9051@med.cornell.edu. 2. Division of General Internal Medicine, Columbia University Medical Center, New York, New York. 3. Division of General Internal Medicine, Weill Cornell Medicine, New York, New York. 4. School of Medicine at Stony Brook University, Stony Brook, New York. 5. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama. 6. Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York. 7. Department of Medicine, University of Pittsburgh; Pittsburgh, Pennsylvania. 8. Division of Geriatrics, Weill Cornell Medicine, New York, New York. 9. Division of Cardiology, Columbia University Medical Center, New York, New York.
Abstract
OBJECTIVES: This study sought to describe the patterns of heart failure (HF)-exacerbating medications used among older adults hospitalized for HF and to examine determinants of HF-exacerbating medication use. BACKGROUND: HF-exacerbating medications can potentially contribute to adverse outcomes and could represent an important target for future strategies to improve post-hospitalization outcomes. METHODS: Medicare beneficiaries ≥65 years of age with an adjudicated HF hospitalization between 2003 and 2014 were derived from the geographically diverse REGARDS (Reasons for Geographic and Racial Difference in Stroke) cohort study. Major HF-exacerbating medications, defined as those listed on the 2016 American Heart Association Scientific Statement listing medications that can precipitate or induce HF, were examined. Patterns of prescribing medications at hospital admission and at discharge were examined, as well as changes that occurred between admission and discharge; and a multivariable logistic regression analysis was conducted to identify determinants of harmful prescribing practices following HF hospitalization (defined as either the continuation of an HF-exacerbating medications or an increase in the number of HF-exacerbating medications between hospital admission and discharge). RESULTS: Among 558 unique individuals, 18% experienced a decrease in the number of HF-exacerbating medications between admission and discharge, 19% remained at the same number, and 12% experienced an increase. Multivariable logistic regression analysis revealed that diabetes (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.18 to 2.75]) and small hospital size (OR: 1.93; 95% CI: 1.18 to 3.16) were the strongest, independently associated determinants of harmful prescribing practices. CONCLUSIONS: HF-exacerbating medication regimens are often continued or started following an HF hospitalization. These findings highlight an ongoing need to develop strategies to improve safe prescribing practices in this vulnerable population.
OBJECTIVES: This study sought to describe the patterns of heart failure (HF)-exacerbating medications used among older adults hospitalized for HF and to examine determinants of HF-exacerbating medication use. BACKGROUND: HF-exacerbating medications can potentially contribute to adverse outcomes and could represent an important target for future strategies to improve post-hospitalization outcomes. METHODS: Medicare beneficiaries ≥65 years of age with an adjudicated HF hospitalization between 2003 and 2014 were derived from the geographically diverse REGARDS (Reasons for Geographic and Racial Difference in Stroke) cohort study. Major HF-exacerbating medications, defined as those listed on the 2016 American Heart Association Scientific Statement listing medications that can precipitate or induce HF, were examined. Patterns of prescribing medications at hospital admission and at discharge were examined, as well as changes that occurred between admission and discharge; and a multivariable logistic regression analysis was conducted to identify determinants of harmful prescribing practices following HF hospitalization (defined as either the continuation of an HF-exacerbating medications or an increase in the number of HF-exacerbating medications between hospital admission and discharge). RESULTS: Among 558 unique individuals, 18% experienced a decrease in the number of HF-exacerbating medications between admission and discharge, 19% remained at the same number, and 12% experienced an increase. Multivariable logistic regression analysis revealed that diabetes (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.18 to 2.75]) and small hospital size (OR: 1.93; 95% CI: 1.18 to 3.16) were the strongest, independently associated determinants of harmful prescribing practices. CONCLUSIONS: HF-exacerbating medication regimens are often continued or started following an HF hospitalization. These findings highlight an ongoing need to develop strategies to improve safe prescribing practices in this vulnerable population.
Authors: Christopher Ody; Lucy Msall; Leemore S Dafny; David C Grabowski; David M Cutler Journal: Health Aff (Millwood) Date: 2019-01 Impact factor: 6.301
Authors: Robert L Page; Cindy L O'Bryant; Davy Cheng; Tristan J Dow; Bonnie Ky; C Michael Stein; Anne P Spencer; Robin J Trupp; JoAnn Lindenfeld Journal: Circulation Date: 2016-07-11 Impact factor: 29.690
Authors: Abir O Kanaan; Jennifer L Donovan; Nerissa P Duchin; Terry S Field; Jennifer Tjia; Sarah L Cutrona; Shawn J Gagne; Lawrence Garber; Peggy Preusse; Leslie R Harrold; Jerry H Gurwitz Journal: J Am Geriatr Soc Date: 2013-10-01 Impact factor: 5.562
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrom; Tina K Schramm; Morten L Hansen; Emil L Fosbøl; Rikke Sørensen; Fredrik Folke; Pernille Buch; Niels Gadsbøll; Søren Rasmussen; Henrik E Poulsen; Lars Køber; Mette Madsen; Christian Torp-Pedersen Journal: Arch Intern Med Date: 2009-01-26
Authors: Jacqueline D Wong; Jana M Bajcar; Gary G Wong; Shabbir M H Alibhai; Jin-Hyeun Huh; Annemarie Cesta; Gregory R Pond; Olavo A Fernandes Journal: Ann Pharmacother Date: 2008-10 Impact factor: 3.154
Authors: Matthew J Crowley; Clarissa J Diamantidis; Jennifer R McDuffie; C Blake Cameron; John W Stanifer; Clare K Mock; Xianwei Wang; Shuang Tang; Avishek Nagi; Andrzej S Kosinski; John W Williams Journal: Ann Intern Med Date: 2017-01-03 Impact factor: 25.391
Authors: Kenneth E Freedland; Brian C Steinmeyer; Robert M Carney; Judith A Skala; Michael W Rich Journal: Gen Hosp Psychiatry Date: 2020-04-25 Impact factor: 3.238
Authors: Melissa R Riester; Parag Goyal; Lan Jiang; Sebhat Erqou; James L Rudolph; John E McGeary; Nicole M Rogus-Pulia; Caroline Madrigal; Lien Quach; Wen-Chih Wu; Andrew R Zullo Journal: J Gen Intern Med Date: 2022-01-03 Impact factor: 6.473
Authors: Diana Jaber; Fabian Vargas; Linh Nguyen; Joanna Ringel; Kate Zarzuela; Mahad Musse; Min Ji Kwak; Emily B Levitan; Mathew S Maurer; Mark S Lachs; Monika M Safford; Parag Goyal Journal: J Card Fail Date: 2021-11-21 Impact factor: 6.592
Authors: Lina M Brinker; Matthew C Konerman; Pedram Navid; Michael P Dorsch; Jennifer McNamara; Cristen J Willer; Mary E Tinetti; Scott L Hummel; Parag Goyal Journal: Am J Med Date: 2020-08-18 Impact factor: 4.965
Authors: Masaki Kobayashi; Min Ji Kwak; David Aguilar; Parag Goyal; Holly M Holmes; Ashish A Deshmukh; Rajender R Aparasu Journal: Am J Cardiol Date: 2021-05-25 Impact factor: 3.133
Authors: Ozan Unlu; Emily B Levitan; Evgeniya Reshetnyak; Jerard Kneifati-Hayek; Ivan Diaz; Alexi Archambault; Ligong Chen; Joseph T Hanlon; Mathew S Maurer; Monika M Safford; Mark S Lachs; Parag Goyal Journal: Circ Heart Fail Date: 2020-10-13 Impact factor: 8.790